SCHEMBL6773731

SCHEMBL6773731

CSc1cccc(C(CNC(=O)CNC(=O)c2cccc(NC(=N)N)c2)C(=O)OC(C)(C)C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.38
RAB9A P51151 2/20 0.38
TP53 P04637 1/20 0.38
TSHR P16473 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
F2 P00734 2/20 0.36
TMPRSS6 Q8IU80 1/20 0.36
POLB P06746 3/20 0.35
NPC1 O15118 1/20 0.35
LMNA P02545 1/20 0.35
CASR P41180 1/20 0.34
ITGB1 P05556 1/20 0.34
ITGA5 P08648 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
STAT3 P40763 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6773735 0.83 TP53 (0.39) SMN1; SMN2RAB9ATP53TSHRNPSR1
SCHEMBL27486478 0.78 GPR139 (0.44) MEN1KMT2AF2ITGB1ITGA5
SCHEMBL6779101 0.77 ITGB3 (0.45) MEN1KMT2AITGB1ITGA5
SCHEMBL242675 0.77 ITGB1 (0.45) MEN1KMT2ANPC1LMNACASR
SCHEMBL23518452 0.75 ALDH1A1 (0.44) SMN1; SMN2RAB9ATP53NPSR1MEN1
SCHEMBL27486186 0.75 ITGB1 (0.39) SMN1; SMN2RAB9ATP53TSHRNPSR1
SCHEMBL7835686 0.72 PTPRC (0.39) PRMT5WDR77F2TMPRSS6CASR
SCHEMBL7339143 0.72 RXFP1 (0.48) SMN1; SMN2RAB9ANPSR1MEN1KMT2A
SCHEMBL244262 0.72 ITGB1 (0.44) SMN1; SMN2MEN1KMT2ALMNACASR
SCHEMBL19426694 0.71 CASR (0.57) MEN1KMT2ANPC1CASRITGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed